key: cord-0778749-cgcahd1d
authors: Temerozo, Jairo R.; Sacramento, Carolina Q.; Fintelman-Rodrigues, Natalia; Pão, Camila R. R.; de Freitas, Caroline S.; Dias, Suelen Silva Gomes; Ferreira, André C.; Mattos, Mayara; Soares, Vinicius Cardoso; Teixeira, Lívia; Azevedo-Quintanilha, Isaclaudia G.; Hottz, Eugenio D.; Kurtz, Pedro; Bozza, Fernando A.; Bozza, Patrícia T.; Souza, Thiago Moreno L.; Bou-Habib, Dumith Chequer
title: VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells
date: 2021-11-07
journal: bioRxiv
DOI: 10.1101/2020.07.25.220806
sha: 1106c0903de9799e6bb4824a83aa45d5b9ae5a95
doc_id: 778749
cord_uid: cgcahd1d

Infection by SARS-CoV-2 may elicit uncontrolled and damaging inflammatory responses. Thus, it is critical to identify compounds able to inhibit virus replication and thwart the inflammatory reaction. Here, we show that the plasma levels of the immunoregulatory neuropeptide VIP are elevated in patients with severe COVID-19, correlating with reduced inflammatory mediators and with survival on those patients. In vitro, VIP and PACAP, highly similar neuropeptides, decreased the SARS-CoV-2 genome replication in human monocytes and viral production in lung epithelial cells, also reducing cell death. Both neuropeptides inhibited the production of proinflammatory mediators in lung epithelial cells and in monocytes. VIP and PACAP prevented in monocytes the SARS-CoV-2-induced activation of NF-kB and SREBP1 and SREBP2, transcriptions factors involved in proinflammatory reactions and lipid metabolism, respectively. They also promoted CREB activation, a transcription factor with antiapoptotic activity and negative regulator of NF-kB. Specific inhibition of NF-kB and SREBP1/2 reproduced the anti-inflammatory, antiviral and cell death protection effects of VIP and PACAP. Our results support further clinical investigations of these neuropeptides against COVID-19.

cytokines was used to establish standard curves and the sensitivity of the assay.

The levels of IL-6, IL-8, TNF-α and MIF were quantified in the supernatants from 177 uninfected and SARS-CoV-2-infected Calu-3 cells and monocytes by ELISA (R&D and a protective ventilation strategy that included low tidal volume (6 mL/kg of 214 predicted body weight) and limited driving pressure (less than 16 cmH2O) as well 215 as optimal PEEP calculated based on the best lung compliance and PaO2/FiO2 Table 1 (Fig. 1A) . Comparing the viral load in positive swab samples from mild and 250 severe COVID-19 patients we found a modest positive correlation with VIP levels 251 (Fig. 1B) . Following, we examined a possible correlation between VIP levels of 252 severe patients and inflammatory markers. We identified that VIP negatively 253 correlated with five pro-inflammatory factors (IL-8, IL-12p40, IL-17A, TNF-α and 254 CXCL10/IP-10), and positively with two anti-inflammatory factors (IL-1RA and IL-10) 255 ( Fig. 1C-I) . Next, severe COVID-19 patients were further subdivided between those 256 requiring invasive mechanical ventilation or noninvasive O2 supplementation or 257 according to the 28-day mortality outcome as survivors or non-survivors. We did not 258 find a significant difference when analyzing O2 supplementation versus mechanical 259 ventilation ( Fig. 1J) , probably due to the low number of patients under the first 260 condition. On the contrary, we observed that VIP plasma levels associated with 261 survival of patients with severe COVID-19, being significantly higher in survivors 262 than in non-survivors (Fig. 1K) . For PACAP plasma levels, we did not find significant of lung epithelial cells highly susceptible to SARS-CoV-2) exposed to VIP or 282 PACAP). We found that VIP reduced the SARS-CoV-2 RNA synthesis in 283 monocytes, achieving up to 40% and 50% inhibition at 5 nM and 10 nM, respectively 284 ( Fig. 2A) . PACAP similarly decreased the levels of viral RNA synthesis with 5 nM 285 and 10 nM (up to 50% for both doses) (Fig. 2B) . We next evaluated whether VIP 286 and PACAP could also be able to restrict virus production in pulmonary cells, one 287 of the major targets of SARS-CoV-2. We found that VIP reduced viral replication, 288 reaching up to 50% and 40% inhibition with 1 nM and 5 nM, respectively ( 2. Activation of VPAC1 at 1 nM, 5 nM and 10 nM, and of VPAC2 at 1 nM, significantly 307 reduced the SARS-CoV-2 genome replication (Fig. 3A) . We also verified that 308 VPAC1 is the main receptor involved the inhibition of SARS-CoV-2 in Calu-3 cells, 309 resembling the level of inhibition achieved with VIP, while the exposure to a VPAC2 310 agonist resulted in a more modest inhibition (Fig. 3B) . The stimulus with a PAC1 311 agonist had no effect on viral replication ( Fig. 3A and 3B) . As a whole, these 312 findings suggest that VPAC1 receptor is the main contributor for the VIP-and CoV-2-infected monocytes (Fig. 5B) , a result coherent with NF-kB activation in the uninfected monocytes ( Fig. 5C and 5D, Supp. Fig. 2) . production of TNF-α and IL-6, and reduced cell death, measurements that were all 371 amplified when the inhibitors were associated with either neuropeptide (Fig. 6, A- with VIP or PACAP, produced similar results (Fig. 6, A-D) . Importantly, the 

Since our results were obtained with the pandemic SARS-CoV-2 D614G, we cannot 505 assure that the VIP and PACAP protective effects will also prevail against emerging 506 variants. Nonetheless, given that both neuropeptides regulate cellular mechanisms, 507 actions that might be independent of virus genotypes, we suppose that their 508 protective effects will likely be replicated against SARS-CoV-2 variants.

As up to now the availability of antivirals specific to SARS-CoV-2 is limited, and that The authors declare no competing financial interests. Each dot represents an independent assay with three replicates. 28-day mortality --13 (54.2%) Comorbidities Obesity 1 (10%) 1 (10%) 5 (20.8%) Hypertension 1 (10%) 2 (20%) 6 (25%) Diabetes 0 (0%) 0 (0%) 9 (37.5%) Cancer 0 (0%) 0 (0%) 3 (12.5%) Heart disease 3 0 (0%) 0 (0%) 2 (8.3%) Presenting symptoms Cough 0 (0%) 3 (30%) 17 (70.8%) Fever 0 (0%) 5 (50%) 18 (75%) Dyspnea 0 (0%) 0 (0%) 20 (83.3%) Headache 0 (0%) 4 (40%) 3 (12.5%)

Monocytes and macrophages, targets of severe acute respiratory syndrome 692 coronavirus 2: The clue for coronavirus disease 2019 immunoparalysis. J 693 Infect Dis

Acute Respiratory Syndrome Coronavirus 2-Induced Immune Activation and 696 Death of Monocyte-Derived Human Macrophages and Dendritic Cells

Activation of VPAC 1 receptors by VIP and PACAP-27 in human 700 bronchial epithelial cells induces CFTR-dependent chloride secretion

Immunohistochemical 703 localization and distribution of VIP/PACAP receptors in human lung

Expression and 706 distribution of vasoactive intestinal polypeptide receptor VPAC2 mRNA in 707 human airways

Analysis of the human tissue-specific expression by genome-wide 710 integration of transcriptomics and antibody-based proteomics

Vasoactive 713 intestinal peptide and pituitary adenylate cyclase-activating polypeptides 714 (PACAP27) and PACAP38) protect CD4+CD8+ thymocytes from 715 glucocorticoid-induced apoptosis

NF-κB signaling in inflammation

The Neuropeptides Vasoactive Intestinal Peptide and 720

Pituitary Adenylate Cyclase-Activating Polypeptide Control HIV-1 Infection in 721

Macrophages Through Activation of Protein Kinases A and C. Front 722 Immunol

Vasoactive intestinal 724 peptide (VIP) and pituitary adenylate cyclase-activating polypeptide 725 (PACAP) induce phosphorylation of the transcription factor CREB in 726 subpopulations of rat pinealocytes: immunocytochemical and 727 immunochemical evidence

Transcriptional control of the inflammatory response: a role for the 729 CREB-binding protein (CBP)

Elevated Cyclic 774 AMP Inhibits NF-κB-mediated Transcription in Human Monocytic Cells

CREB 777 pathway links PGE2 signaling with macrophage polarization

Suppression of Proinflammatory Cytokines Interleukin-1 and Tumor 780

Necrosis Factor-in Astrocytes by a V1 Vasopressin Receptor Agonist: A 781 cAMP Response Element-Binding Protein-Dependent Mechanism

Tonks A, et 784 al. DPPC regulates COX-2 expression in monocytes via phosphorylation of

Exclusive Temporal Stimulation of IL-10 Expression in LPS

Mouse Macrophages by cAMP Inducers and Type I Interferons. Front 789 Immunol

Inflammatory signal 791 induced IL-10 production of marginal zone B-cells depends on CREB

Role of CREB in modulation of TNFα 794 and IL-10 expression in LPS-stimulated

Signaling Pathways and Genes that Inhibit Pathogen-Induced Macrophage

CREB is 801 a critical regulator of normal hematopoiesis and leukemogenesis

SREBP-regulated lipid metabolism: convergent 804 physiology -divergent pathophysiology

Constitutive 807 formation of oligomeric complexes between family B G protein-coupled 808 vasoactive intestinal polypeptide and secretin receptors

Prospect of vasoactive intestinal peptide therapy for 811

COPD/PAH and asthma: a review

Reference values of C reactive Protein (0.00 -1.00), Fibrinogen (238 -498 mg/dL) and 936 D-dimer (0 -500 ng/mL)

The qualitative variables were compared using the two tailed 938 Fisher exact test, and the numerical variables using the t test for parametric and the Mann 939

Whitney U test for nonparametric distributions